Human platelet vasopressin receptors

Berrettini, Wade H.; Post, Robert M.; Worthington, Emma; Casper, John B.

doi:10.1016/0024-3205(82)90458-1

Cited by 34 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7). The presence of vasopressin on platelets is also consistent with the report of Berrettini et al 36 who found that platelets have vasopressin receptors with binding characteristics similar to those reported for renal tissue. 37 Nonetheless, all of these pieces of evidence are circumstantial, and other studies will be required to definitively identify and also to explain the role of platelet vasopressin.…”

Section: -137supporting

confidence: 81%

Plasma and platelet vasopressin in essential hypertension and congestive heart failure.

Preibisz¹,

Sealey²,

Laragh³

et al. 1983

Hypertension

157

View full text Add to dashboard Cite

SUMMARY In this study we found that, in 31 normal subjects, close to 90% of circulating arginine vasopressin (AVP), measured by radiolmmunoassay, was associated with platelets. By using routine methods of centrifugation, which do not completely separate platelets, the normal range of plasma vasopressin was higher by twofold than the normal range in platelet-free plasma prepared by differential centrifugation, which was 1.4 ± 1.0 SD pg/ml. Platelet vasopressin was 12.9 ± 5.7 pg/ml. Patients with congestive heart failure had, on average, an elevated platelet-free plasma AVP, as did two patients with thrombocytopenia and one with thrombocytosis. Patients with essential hypertension had slightly high levels of platelet-free plasma AVP and demonstrated an abnormal inverse relationship between platelet-free plasma AVP and serum osmolality. Immunoreactive platelet vasopressin was slightly low in patients with essential hypertension and was subnormal in patients with congestive heart failure. These studies demonstrate that platelets normally present in centrifuged plasma cause an overestimation of the plasma vasopressin levels. Until the physiological meaning of plasma and platelet-bound AVP is understood, studies of circulating vasopressin should probably assess both plasma and platelet AVP levels. 2 Moreover, vasopressin is reported to be involved in various forms.of experimental hypertension, 1 * 9 and lesions of the medulla oblongata have been shown to cause excessive release and acute hypertension. 10 In addition, elevations of urine and plasma vasopressin have been reported in some patients with hypertension"" 13 despite the presence of lower serum sodium. 13On the other hand, the role of vasopressin in the maintenance of hypertension is controversial, 14 " 17 and there is evidence to suggest that vasopressin cannot maintain chronic hypertension because of a compen- Nonetheless, measurements of circulating vasopressin in human hypertension may be of value by providing clues to underlying mechanisms. Vasopressin is released into the circulation in response to either osmotic stimuli or volume-dependent baroreceptor-mediated stimuli. "23 Therefore, assessment of vasopressin levels in relation to serum osmolality should provide evidence of which mechanism is operative in patients who have abnormal levels of vasopressin.In the present study we evaluated arginine vasopressin (AVP) levels in relation to the serum osmolality, in a group of untreated patients with essential hypertension. In the course of this investigation, using a sensitive radioimmunoassay method for vasopressin, 24 we observed abnormally high levels in plasma samples that were contaminated with the buffy coat. We then found that vasopressin levels measured in a platelet fraction were close to tenfold higher than in plateletfree plasma and, that platelet-free plasmas had significantly lower values than in most previous reports. 22 In this paper we report these findings and also the results of vasopressin measurements in platelets and platelet-

show abstract

Section: -137supporting

confidence: 81%

Plasma and platelet vasopressin in essential hypertension and congestive heart failure.

Preibisz¹,

Sealey²,

Laragh³

et al. 1983

Hypertension

157

View full text Add to dashboard Cite

show abstract

“…This suggests that there is a reversible and saturable binding of AVP to platelets, in accordance with previous observations (Berrettini et al, 1982;Vittet et al, 1986). The binding was dependent on the incubation time, temperature and concentration of tracer, and was displaced by the addition of unlabelled AVP and EDTA-2Na.…”

Section: Discussionsupporting

confidence: 91%

Characterization of Human Platelet Vasopressin Receptor and the Relation Between Vasopressin‐induced Platelet Aggregation and Vasopressin Binding to Platelets

Inaba

Umeda

Yamane

et al. 1988

Clinical Endocrinology

View full text Add to dashboard Cite

Immunoreactive AVP was found to be much higher in platelets than in platelet-free plasma (PFP) in normal subjects (12.8 +/- 6.3 versus 1.7 +/- 0.8 fmol/ml). AVP levels in PFP were appreciably elevated in parallel with the elevation of plasma osmolality induced by the acute osmotic stimulation, while the AVP levels in platelets did not change before and after the stimulation. Binding studies on intact platelets demonstrated specific binding sites for [3H]AVP. The specific binding was time, temperature and concentration-dependent, saturable and reversible, with the maximal binding capacity (Bmax) of 169.9 +/- 14.4 sites/platelet and affinity of 4.84 +/- 1.15 x 10(8)M-1. The affinity constants for unlabelled AVP, lysine vasopressin (LVP), oxytocin (OT) and dDAVP were 9.0, 8.5, 7.4 and 6.6, respectively, and the inhibition constant for d(CH2)5Tyr(Me)AVP (V1-antagonist) was 7.7. There was a highly significant correlation between the affinity constants of AVP analogues and their relative vasopressor activities in vivo, whereas no such correlation was found between the affinity constants and antidiuretic activities. AVP caused platelet aggregation with the maximal aggregation of 48.0 +/- 25.1% at 230 nM of AVP. A significant correlation was observed between the maximal percentage aggregation and Bmax of [3H]AVP to intact platelets. These results suggest that the platelet vasopressin receptor belongs to the V1 vascular subtype and mediates platelet aggregation.

show abstract

“…Carbamazepine has also been recently reported to bind directly to human platelet AVP receptors (38).…”

Section: Discussionmentioning

confidence: 99%

Carbamazepine Diminishes the Sensitivity of the Plasma Arginine Vasopressin Response to Osmotic Stimulation

Gold

Robertson

Ballenger

et al. 1983

The Journal of Clinical Endocrinology & Metabolism

Self Cite

View full text Add to dashboard Cite

Carbamazepine, a drug used to treat manic-depressive illness, has been reported to possess antidiuretic properties, but its effects on arginine vasopressin (AVP) secretion are controversial. Consequently, we examined plasma AVP secretion during hypertonic (5%) saline infusion in seven manic-depressive patients while on placebo and after 3-5 weeks of carbamazepine treatment. We also measured carbamazepine's effects on basal levels of the hormone in cerebrospinal fluid. Carbamazepine significantly reduced the sensitivity of the plasma AVP response to osmotic stimulation without affecting the osmotic threshold for AVP secretion. Moreover, carbamazepine did not affect baseline weight, plasma osmolality, plasma sodium, urine output, plasma AVP, or cerebrospinal fluid AVP. Although the functional significance of these findings remain to be fully determined, the fact that carbamazepine significantly reduced AVP secretion without inducing diuresis supports previous suggestions that carbamazepine enhances renal responsivity to available AVP. In addition, since carbamazepine failed to affect the osmotic threshold, the reported cases of carbamazepine-induced inappropriate AVP secretion and water intoxication must be very uncommon and probably represent idiosyncratic responses.

show abstract

Human platelet vasopressin receptors

Cited by 34 publications

References 21 publications

Plasma and platelet vasopressin in essential hypertension and congestive heart failure.

Plasma and platelet vasopressin in essential hypertension and congestive heart failure.

Characterization of Human Platelet Vasopressin Receptor and the Relation Between Vasopressin‐induced Platelet Aggregation and Vasopressin Binding to Platelets

Carbamazepine Diminishes the Sensitivity of the Plasma Arginine Vasopressin Response to Osmotic Stimulation

Contact Info

Product

Resources

About